1. NADPH Oxidases: Insights into Selected Functions and Mechanisms of Action in Cancer and Stem Cells
    Magdalena Skonieczna et al, 2017, Oxidative Medicine and Cellular Longevity CrossRef
  2. Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells
    Hengqiang Zhao et al, 2017, J. Cell. Mol. Med. CrossRef
  3. Mechanistic Evaluation and Translational Signature of Gemcitabine-induced Chemoresistance by Quantitative Phosphoproteomics Analysis with iTRAQ Labeling Mass Spectrometry
    Qingke Duan et al, 2017, Sci Rep CrossRef
  4. Differential role of Hedgehog signaling in human pancreatic (patho-) physiology: An up to date review
    Eckhard Klieser et al, 2016, WJGP CrossRef
  5. Leptin signaling and cancer chemoresistance: Perspectives
    Pierre V Candelaria et al, 2017, WJCO CrossRef
  6. Implication of 4E-BP1 protein dephosphorylation and accumulation in pancreatic cancer cell death induced by combined gemcitabine and TRAIL
    Androulla Elia et al, 2017, Cell Death Dis CrossRef
  7. Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells
    Xu Zhu et al, 2018, Front. Pharmacol. CrossRef
  8. null
    Nils Elander et al, 2018 CrossRef
  9. Bitter melon juice exerts its efficacy against pancreatic cancer via targeting both bulk and cancer stem cells
    Deepanshi Dhar et al, 2018, Molecular Carcinogenesis CrossRef
  10. Dual delivery nanoscale device for miR-345 and gemcitabine Co-delivery to treat pancreatic cancer
    Uz Metin et al, 2018, Journal of Controlled Release CrossRef
  11. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis
    Divya Thomas et al, 2019, Mol Cancer CrossRef
  12. Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer
    Srinivasa P Pothula et al, 2016, Br J Cancer CrossRef
  13. FOXO3 is essential for CD44 expression in pancreatic cancer cells
    M Kumazoe et al, 2017, Oncogene CrossRef
  14. Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells
    K E Richards et al, 2017, Oncogene CrossRef
  15. Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment
    Tessa Ya Sung Le Large et al, 2019, Ther Adv Med Oncol CrossRef
  16. null
    Nils Elander et al, 2017 CrossRef
  17. The ionophore antibiotic gramicidin A inhibits pancreatic cancer stem cells associated with CD47 down-regulation
    Rui-Qi Wang et al, 2019, Cancer Cell Int CrossRef
  18. Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies
    Murielle Mimeault et al, 2014, Molecular Aspects of Medicine CrossRef
  19. PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic
    Anne-Laure Papa et al, 2013, Cell Oncol. CrossRef
  20. Mesenchymal stem cells preserve their stem cell traits after exposure antimetabolite chemotherapy
    Ramon Lopez Perez et al, 2019, Stem Cell Research CrossRef
  21. Slug contributes to gemcitabine resistance through epithelial-mesenchymal transition in CD133+ pancreatic cancer cells
    Koichiro Tsukasa et al, 2015, Human Cell CrossRef
  22. Promising molecular mechanisms responsible for gemcitabine resistance in cancer
    Yanfei Jia et al, 2015, Genes & Diseases CrossRef
  23. Wnt/β-Catenin Signaling: The Culprit in Pancreatic Carcinogenesis and Therapeutic Resistance.
    Monish Ram Makena et al, 2019, Int J Mol Sci CrossRef
  24. The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer.
    Pingting Zhou et al, 2017, Mol Cancer CrossRef
  25. PDE3 inhibitor and EGCG combination treatment suppress cancer stem cell properties in pancreatic ductal adenocarcinoma
    Motofumi Kumazoe et al, 2017, Sci Rep CrossRef
  26. The FOXO3/PGC-1β signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma
    Motofumi Kumazoe et al, 2017, J. Biol. Chem. CrossRef
  27. Attenuation of hedgehog/GLI signaling by NT1721 extends survival in pancreatic cancer.
    Claudia M Kowolik et al, 2019, J Exp Clin Cancer Res CrossRef
  28. Establishment and Characterization of Paired Primary Cultures of Human Pancreatic Cancer Cells and Stellate Cells Derived from the Same Tumor
    Manoj Amrutkar et al, 2020, Cells CrossRef
  29. Prognostic significance of stem cell/ epithelial-mesenchymal transition markers in periampullary/pancreatic cancers: FGFR1 is a promising prognostic marker
    Yosep Chong et al, 2020, BMC Cancer CrossRef
  30. Induced cancer stem cells generated by radiochemotherapy and their therapeutic implications.
    Xiewan Chen et al, 2017, Oncotarget CrossRef
  31. Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma
    Qi Wu et al, 2017, Oncotarget CrossRef
  32. Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer
    Srinivasa P. Pothula et al, 2017, Oncotarget CrossRef
  33. Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models
    Martina D'Aronzo et al, 2015, Oncotarget CrossRef
  34. Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment
    Agnieszka A. Rucki et al, 2017, Mol Cancer Ther CrossRef
  35. CLIC4, ERp29, and Smac/DIABLO Derived from Metastatic Cancer Stem–like Cells Stratify Prognostic Risks of Colorectal Cancer
    Yong-Jian Deng et al, 2014, Clin Cancer Res CrossRef
  36. Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery
    Huang-Chiao Huang et al, 2018, Cancer Res CrossRef
  37. Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells
    Michael Timaner et al, 2018, Cancer Res CrossRef
  38. Morphological Heterogeneity in Pancreatic Cancer Reflects Structural and Functional Divergence
    Petra Sántha et al, 2021, Cancers CrossRef
  39. The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells
    Yibo Fu et al, 2021, Cells CrossRef
  40. The Role of the Hedgehog Pathway in Chemoresistance of Gastrointestinal Cancers
    Yabing Liang et al, 2021, Cells CrossRef
  41. Advances of Tumorigenesis, Diagnosis at Early Stage, and Cellular Immunotherapy in Gastrointestinal Malignancies
    Haipeng Zhu et al, 2021, Front. Oncol. CrossRef
  42. M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer
    Yongmei Zhao et al, 2021, Pharmaceutics CrossRef
  43. CD95L Inhibition Impacts Gemcitabine-Mediated Effects and Non-Apoptotic Signaling of TNF-α and TRAIL in Pancreatic Tumor Cells
    Khalid Rashid et al, 2021, Cancers CrossRef
  44. Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus
    Dakota W. Goad et al, 2022, Molecular Therapy - Oncolytics CrossRef
  45. SOX9 Triggers Different Epithelial to Mesenchymal Transition States to Promote Pancreatic Cancer Progression
    Estefania Carrasco-Garcia et al, 2022, Cancers CrossRef
  46. microRNA-497 prevents pancreatic cancer stem cell gemcitabine resistance, migration, and invasion by directly targeting nuclear factor kappa B 1
    Qiangfeng Yu et al, 2022, Aging CrossRef
  47. Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma
    Manoj Amrutkar et al, 2022, Molecular Oncology CrossRef
  48. Prognostic Significance of Integrin Subunit Alpha 2 (ITGA2) and Role of Mechanical Cues in Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma (PDAC)
    Alessandro Gregori et al, 2023, Cancers CrossRef
  49. Clinical Significance of Overexpression of Oct4 in Advanced Stage Gallbladder Carcinoma
    Deepika Singh et al, 2023, J Gastrointest Canc CrossRef
  50. Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC)
    Md Maksudul Alam et al, 2023, Oncotarget CrossRef
  51. microRNAs Associated with Gemcitabine Resistance via EMT, TME, and Drug Metabolism in Pancreatic Cancer
    Naotake Funamizu et al, 2023, Cancers CrossRef
  52. Co-delivery of gemcitabine and Triapine by calcium carbonate nanoparticles against chemoresistant pancreatic cancer
    Yongmei Zhao et al, 2023, International Journal of Pharmaceutics CrossRef
  53. Chemomodulatory Effect of the Marine-Derived Metabolite “Terrein” on the Anticancer Properties of Gemcitabine in Colorectal Cancer Cells
    Reham Khaled Abuhijjleh et al, 2023, Marine Drugs CrossRef
  54. PPAR/PDK4 pathway is involved in the anticancer effects of cGMP in pancreatic cancer
    Mai Yamashita et al, 2023, Biochemical and Biophysical Research Communications CrossRef
  55. HGF/c-Met pathway inhibition combined with chemotherapy increases cytotoxic T-cell infiltration and inhibits pancreatic tumour growth and metastasis
    Alpha Raj Mekapogu et al, 2023, Cancer Letters CrossRef
  56. 1,3,4-Oxadiazole and 1,3,4-Thiadiazole Nortopsentin Derivatives against Pancreatic Ductal Adenocarcinoma: Synthesis, Cytotoxic Activity, and Inhibition of CDK1
    Daniela Carbone et al, 2023, Marine Drugs CrossRef
  57. Lipid-like gemcitabine diester-loaded liposomes for improved chemotherapy of pancreatic cancer
    Xiaowei Wang et al, 2024, Journal of Controlled Release CrossRef
  58. Stepwise optimization of tumor-targeted dual-action platinum(iv)-gemcitabine prodrugs
    Alexander Kastner et al, 2024, Inorg. Chem. Front. CrossRef
  59. Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model
    Md. Hafiz Uddin et al, 2023, Clinical & Translational Med CrossRef
  60. Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer
    Masahiro Uehara et al, 2024, Cancer Drug Resist CrossRef
  61. Pharmacological mechanisms underlying the interaction of the nucleoside analogue gemcitabine with the c-MET inhibitor tivantinib in pancreatic cancer
    Mahrou Vahabi et al, 2024, Nucleosides, Nucleotides & Nucleic Acids CrossRef
  62. The nuclear export protein exportin‐1 in solid malignant tumours: From biology to clinical trials
    Chuanxi Lai et al, 2024, Clinical & Translational Med CrossRef
  63. Hedgehog Signaling in Cancer: A Prospective Therapeutic Target for Eradicating Cancer Stem Cells.
    Ita Novita Sari et al, 2018, Cells CrossRef
  64. Role of Wnt/β-catenin pathway in cancer drug resistance: Insights into molecular aspects of major solid tumors.
    Charudatt Samant et al, 2024, Biochem Biophys Res Commun CrossRef
  65. Characterization of equilibrative nucleoside transport of the pancreatic cancer cell line: Panc-1
    Sila Appak Baskoy et al, 2023, tjps CrossRef
  66. Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review
    Tomas Koltai et al, 2022, Cancers CrossRef
  67. Unravelling the complexities of resistance mechanism in pancreatic cancer: insights from in vitro and ex-vivo model systems
    Giulia Lencioni et al, 2024, Seminars in Cancer Biology CrossRef
  68. Prediction of synergistic gemcitabine-based combination treatment through a novel tumor stemness biomarker NANOG in pancreatic cancer
    Jiongjia Cheng et al, 2024, RSC Med. Chem. CrossRef
  69. Correlation Between Antihypertensive Drugs and Survival Among Patients with Pancreatic Ductal Adenocarcinoma
    Natalia Kluz et al, 2024, Cancers CrossRef
  70. Improved Antitumor Efficiency of N4-Tetradecyloxycarbonyl Gemcitabine-Loaded Liposomes for Pancreatic Cancer Chemotherapy
    Dan Wang et al, 2024, IJN CrossRef